Related references
Note: Only part of the references are listed.Cbx2 Targets PRC1 to Constitutive Heterochromatin in Mouse Zygotes in a Parent-of-Origin-Dependent Manner
Mathieu Tardat et al.
MOLECULAR CELL (2015)
Polycomb-mediated silencing in neuroendocrine prostate cancer
Pier-Luc Clermont et al.
CLINICAL EPIGENETICS (2015)
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Merritt P. Edlind et al.
ASIAN JOURNAL OF ANDROLOGY (2014)
Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role
P-L Clermont et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
Dong Lin et al.
CANCER RESEARCH (2014)
Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis-A Systematic Review and Pooled Analysis
Hai Tao Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cbx2 stably associates with mitotic chromosomes via a PRC2-or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes
Chao Yu Zhen et al.
MOLECULAR BIOLOGY OF THE CELL (2014)
High-risk prostate cancer-classification and therapy
Albert J. Chang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prostate cancer: ESMO Consensus Conference Guidelines 2012
A. Horwich et al.
ANNALS OF ONCOLOGY (2013)
Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation
Karin Klauke et al.
NATURE CELL BIOLOGY (2013)
Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues
Gary C. Hon et al.
NATURE GENETICS (2013)
PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes
Zhonghua Gao et al.
MOLECULAR CELL (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
Francesco Crea et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Recognition and Specificity Determinants of the Human Cbx Chromodomains
Lilia Kaustov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Rajnish A. Gupta et al.
NATURE (2010)
The epigenome as a therapeutic target in prostate cancer
Antoinette S. Perry et al.
NATURE REVIEWS UROLOGY (2010)
Ovaries and Female Phenotype in a Girl with 46,XY Karyotype and Mutations in the CBX2 Gene
Anna Biason-Lauber et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Novel motifs distinguish multiple homologues of Polycomb in vertebrates: expansion and diversification of the epigenetic toolkit
Ramamoorthy Senthilkumar et al.
BMC GENOMICS (2009)
An operational definition of epigenetics
Shelley L. Berger et al.
GENES & DEVELOPMENT (2009)
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis
Dong Lin et al.
CANCER RESEARCH (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
Daniel R. Rhodes et al.
NEOPLASIA (2007)
Gene expression in the LNCaP human prostate cancer progression model: Progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo
Qian Chen et al.
CANCER LETTERS (2006)
Mouse Polycomb M33 is required for splenic vascular and adrenal gland formation through regulating Ad4BP/SF1 expression
Y Katoh-Fukui et al.
BLOOD (2005)
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines
AY Liu et al.
PROSTATE (2004)
Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice
N Coré et al.
ONCOGENE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
Share Paper
